ASX - By Stock
|
PAA |
Re:
Ann: Application for quotation of securities - PAA
|
|
Densy
|
10 |
2.9K |
11 |
27/06/24 |
27/06/24 |
ASX - By Stock
|
10
|
2.9K
|
11
|
|
ASX - By Stock
|
PAA |
Share Purchase Plan (SPP)
|
|
Densy
|
6 |
2.4K |
53 |
24/06/24 |
24/06/24 |
ASX - By Stock
|
6
|
2.4K
|
53
|
|
ASX - By Stock
|
PAA |
Re:
Ann: PharmAust Presentation
|
|
Densy
|
91 |
22K |
24 |
24/06/24 |
24/06/24 |
ASX - By Stock
|
91
|
22K
|
24
|
|
ASX - By Stock
|
PAA |
Re:
Ann: PharmAust Presentation
|
|
Densy
|
91 |
22K |
10 |
21/06/24 |
21/06/24 |
ASX - By Stock
|
91
|
22K
|
10
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Proposed issue of securities - PAA
|
|
Densy
|
15 |
3.1K |
15 |
21/06/24 |
21/06/24 |
ASX - By Stock
|
15
|
3.1K
|
15
|
|
ASX - By Stock
|
PAA |
Re:
Ann: PharmAust raises $10 million via Placement and announces SPP
|
|
Densy
|
20 |
6.5K |
22 |
21/06/24 |
21/06/24 |
ASX - By Stock
|
20
|
6.5K
|
22
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Trading Halt
|
|
Densy
|
159 |
38K |
8 |
21/06/24 |
21/06/24 |
ASX - By Stock
|
159
|
38K
|
8
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Trading Halt
|
|
Densy
|
159 |
38K |
19 |
20/06/24 |
20/06/24 |
ASX - By Stock
|
159
|
38K
|
19
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Trading Halt
|
|
Densy
|
159 |
38K |
15 |
20/06/24 |
20/06/24 |
ASX - By Stock
|
159
|
38K
|
15
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Trading Halt
|
|
Densy
|
159 |
38K |
8 |
20/06/24 |
20/06/24 |
ASX - By Stock
|
159
|
38K
|
8
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Trading Halt
|
|
Densy
|
159 |
38K |
10 |
19/06/24 |
19/06/24 |
ASX - By Stock
|
159
|
38K
|
10
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Trading Halt
|
|
Densy
|
159 |
38K |
16 |
19/06/24 |
19/06/24 |
ASX - By Stock
|
159
|
38K
|
16
|
|
ASX - By Stock
|
PAA |
Re:
STRIKE Trial - Phase 2 / 3 - The final frontier to commercial outcome
|
|
Densy
|
49 |
11K |
8 |
11/06/24 |
11/06/24 |
ASX - By Stock
|
49
|
11K
|
8
|
|
ASX - By Stock
|
PAA |
Re:
Ann: OLE Study update reveals impressive Survival Data
|
|
Densy
|
206 |
53K |
30 |
06/06/24 |
06/06/24 |
ASX - By Stock
|
206
|
53K
|
30
|
|
ASX - By Stock
|
PAA |
Re:
Ann: OLE Study update reveals impressive Survival Data
|
|
Densy
|
206 |
53K |
30 |
06/06/24 |
06/06/24 |
ASX - By Stock
|
206
|
53K
|
30
|
|
ASX - By Stock
|
PAA Biotech |
Re:
PAA, A New Dawn , FDA ODD Approval and Entering Phase II MND Trial
|
|
Densy
|
694 |
174K |
22 |
06/06/24 |
06/06/24 |
ASX - By Stock
|
694
|
174K
|
22
|
|
ASX - By Stock
|
PAA |
Re:
Pipeline-in-a-drug
|
|
Densy
|
61 |
12K |
32 |
05/06/24 |
05/06/24 |
ASX - By Stock
|
61
|
12K
|
32
|
|
ASX - By Stock
|
PAA |
Re:
Ann: OLE Study update reveals impressive Survival Data
|
|
Densy
|
206 |
53K |
13 |
05/06/24 |
05/06/24 |
ASX - By Stock
|
206
|
53K
|
13
|
|
ASX - By Stock
|
PAA |
Re:
Ann: OLE Study update reveals impressive Survival Data
|
|
Densy
|
206 |
53K |
45 |
05/06/24 |
05/06/24 |
ASX - By Stock
|
206
|
53K
|
45
|
|
ASX - By Stock
|
PAA Biotech |
Re:
PAA, A New Dawn , FDA ODD Approval and Entering Phase II MND Trial
|
|
Densy
|
694 |
174K |
26 |
04/06/24 |
04/06/24 |
ASX - By Stock
|
694
|
174K
|
26
|
|
ASX - By Stock
|
PAA Biotech |
Re:
PAA, A New Dawn , FDA ODD Approval and Entering Phase II MND Trial
|
|
Densy
|
694 |
174K |
17 |
21/05/24 |
21/05/24 |
ASX - By Stock
|
694
|
174K
|
17
|
|
ASX - By Stock
|
PAA Biotech |
Re:
PAA, A New Dawn , FDA ODD Approval and Entering Phase II MND Trial
|
|
Densy
|
694 |
174K |
29 |
21/05/24 |
21/05/24 |
ASX - By Stock
|
694
|
174K
|
29
|
|
ASX - By Stock
|
PAA Biotech |
Re:
PAA, A New Dawn , FDA ODD Approval and Entering Phase II MND Trial
|
|
Densy
|
694 |
174K |
10 |
21/05/24 |
21/05/24 |
ASX - By Stock
|
694
|
174K
|
10
|
|
ASX - By Stock
|
PAA Biotech |
Re:
PAA, A New Dawn , FDA ODD Approval and Entering Phase II MND Trial
|
|
Densy
|
694 |
174K |
20 |
21/05/24 |
21/05/24 |
ASX - By Stock
|
694
|
174K
|
20
|
|
ASX - By Stock
|
PAA Biotech |
Re:
PAA, A New Dawn , FDA ODD Approval and Entering Phase II MND Trial
|
|
Densy
|
694 |
174K |
14 |
21/05/24 |
21/05/24 |
ASX - By Stock
|
694
|
174K
|
14
|
|
ASX - By Stock
|
PAA Biotech |
Re:
PAA, A New Dawn , FDA ODD Approval and Entering Phase II MND Trial
|
|
Densy
|
694 |
174K |
13 |
21/05/24 |
21/05/24 |
ASX - By Stock
|
694
|
174K
|
13
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Investor update
|
|
Densy
|
86 |
21K |
14 |
17/05/24 |
17/05/24 |
ASX - By Stock
|
86
|
21K
|
14
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Investor update
|
|
Densy
|
86 |
21K |
29 |
17/05/24 |
17/05/24 |
ASX - By Stock
|
86
|
21K
|
29
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Investor update
|
|
Densy
|
86 |
21K |
18 |
17/05/24 |
17/05/24 |
ASX - By Stock
|
86
|
21K
|
18
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Investor update
|
|
Densy
|
86 |
21K |
11 |
17/05/24 |
17/05/24 |
ASX - By Stock
|
86
|
21K
|
11
|
|
ASX - By Stock
|
PAA Biotech |
Re:
PAA, A New Dawn , FDA ODD Approval and Entering Phase II MND Trial
|
|
Densy
|
694 |
174K |
8 |
17/05/24 |
17/05/24 |
ASX - By Stock
|
694
|
174K
|
8
|
|
ASX - By Stock
|
PAA Biotech |
Re:
PAA, A New Dawn , FDA ODD Approval and Entering Phase II MND Trial
|
|
Densy
|
694 |
174K |
23 |
17/05/24 |
17/05/24 |
ASX - By Stock
|
694
|
174K
|
23
|
|
ASX - By Stock
|
PAA Biotech |
Re:
The Final Charge , Phase I/II MND Results & FDA ODD Approval Catalyst
|
|
Densy
|
1.4K |
366K |
47 |
16/05/24 |
16/05/24 |
ASX - By Stock
|
1.4K
|
366K
|
47
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Board Changes
|
|
Densy
|
250 |
64K |
19 |
13/05/24 |
13/05/24 |
ASX - By Stock
|
250
|
64K
|
19
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Board Changes
|
|
Densy
|
250 |
64K |
46 |
10/05/24 |
10/05/24 |
ASX - By Stock
|
250
|
64K
|
46
|
|
ASX - By Stock
|
PAA |
Re:
Corporate action
|
|
Densy
|
239 |
65K |
34 |
06/05/24 |
06/05/24 |
ASX - By Stock
|
239
|
65K
|
34
|
|
ASX - By Stock
|
PAA |
Re:
Corporate action
|
|
Densy
|
239 |
65K |
85 |
06/05/24 |
06/05/24 |
ASX - By Stock
|
239
|
65K
|
85
|
|
ASX - By Stock
|
PAA |
Corporate action
|
|
Densy
|
239 |
65K |
65 |
03/05/24 |
03/05/24 |
ASX - By Stock
|
239
|
65K
|
65
|
|
ASX - By Stock
|
PAA |
Re:
Top PAAO Holders Movements as at 30 April 2024
|
|
Densy
|
4 |
1.7K |
1 |
01/05/24 |
01/05/24 |
ASX - By Stock
|
4
|
1.7K
|
1
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Appendix 4C & Quarterly Update
|
|
Densy
|
104 |
20K |
9 |
01/05/24 |
01/05/24 |
ASX - By Stock
|
104
|
20K
|
9
|
|
ASX - By Stock
|
PAA Biotech |
Re:
The Final Charge , Phase I/II MND Results & FDA ODD Approval Catalyst
|
|
Densy
|
1.4K |
366K |
32 |
18/04/24 |
18/04/24 |
ASX - By Stock
|
1.4K
|
366K
|
32
|
|
ASX - By Stock
|
PAA |
Re:
Ann: PharmAust makes Head of Manufacturing appointment
|
|
Densy
|
37 |
9.6K |
20 |
18/04/24 |
18/04/24 |
ASX - By Stock
|
37
|
9.6K
|
20
|
|
ASX - By Stock
|
PAA |
Re:
PharmAust media thread
|
|
Densy
|
317 |
83K |
19 |
17/04/24 |
17/04/24 |
ASX - By Stock
|
317
|
83K
|
19
|
|
ASX - By Stock
|
PAA Biotech |
Re:
The Final Charge , Phase I/II MND Results & FDA ODD Approval Catalyst
|
|
Densy
|
1.4K |
366K |
36 |
06/04/24 |
06/04/24 |
ASX - By Stock
|
1.4K
|
366K
|
36
|
|
ASX - By Stock
|
PAA Biotech |
Re:
The Final Charge , Phase I/II MND Results & FDA ODD Approval Catalyst
|
|
Densy
|
1.4K |
366K |
29 |
05/04/24 |
05/04/24 |
ASX - By Stock
|
1.4K
|
366K
|
29
|
|
ASX - By Stock
|
PAA Biotech |
Re:
The Great Pharmaust FDA ODD Approval Sweepstake
|
|
Densy
|
222 |
49K |
3 |
02/04/24 |
02/04/24 |
ASX - By Stock
|
222
|
49K
|
3
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Media clarification
|
|
Densy
|
62 |
18K |
14 |
02/04/24 |
02/04/24 |
ASX - By Stock
|
62
|
18K
|
14
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Media clarification
|
|
Densy
|
62 |
18K |
29 |
02/04/24 |
02/04/24 |
ASX - By Stock
|
62
|
18K
|
29
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Media clarification
|
|
Densy
|
62 |
18K |
20 |
02/04/24 |
02/04/24 |
ASX - By Stock
|
62
|
18K
|
20
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Media clarification
|
|
Densy
|
62 |
18K |
7 |
02/04/24 |
02/04/24 |
ASX - By Stock
|
62
|
18K
|
7
|
|